Study on the effect of 40 Hz non-invasive light therapy system. A protocol for a randomized, double-blinded, placebo-controlled clinical trial.
Level 5 - mechanism / opinion, no new human data
Study protocol without reported trial results
PubMed 37901795 · doi:10.3389/fnagi.2023.1250626
What was done
This protocol describes the ALZLIGHT trial, a single-center, randomized, double-blind, placebo-controlled, parallel-group trial. A planned cohort of 62 patients with mild-to-moderate Alzheimer's disease will undergo a 1-month enrollment period, 6 months of daily intervention with either an active 40 Hz non-invasive Invisible Spectral Flicker Light Therapy System or a placebo device, and a 1.5-month post-intervention follow-up. Safety and efficacy are evaluated via a multidisciplinary assessment battery.
What was found
No clinical data or outcomes are reported; the abstract presents only the trial protocol and rationale.
Why it matters
The protocol outlines a standardized approach to test whether non-invasive 40 Hz visual brain stimulation can elicit therapeutic gamma oscillations and slow clinical decline in Alzheimer's disease.
Limits
This paper contains no empirical results or safety findings. The planned trial is limited by a single-center design and a small target sample size (n = 62).
Cited by
- context OptoCeutics' EVY LIGHT 40 Hz light device achieves a 94% adherence rate and produces significant improvements in mood, energy, focus, sleep, and memory.